Program
dulaglutide
Also written as “Dulaglutide”, “LY2189265” and “Dulaglutide (Reference)”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Cardiovascular Diseases, led by 3 companies.
Drug pageDulaglutide: every studyAll 78 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 451 open or running | phase 4since Apr 21, 2016 | Feb 28, 2008 | Dec 2027phase 3 · NCT06739122 |
| CSPC Pharmaceutical Groupits history only | 10 open or running | phase 3since Jan 23, 2024 | Jan 23, 2024 | none ahead |
| Innovent Biologics | 10 open or running | phase 3since Oct 19, 2022 | Oct 19, 2022 | none ahead |
Also a collaborator on its studies: United BioSource and Tessella.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Innovent Biologics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 19, 2022First study: phase 3 study in Diabetes Mellitus, Type 2First studyNCT05606913 · 731 enrolled · China
TargetBeta
“A glucagon-like peptide-1 (GLP-1) receptor agonist that is 90% homologous to native human GLP-1 (7-37) and is composed of a dipeptidyl peptidase-IV-protected GLP-1 analog covalently ”NCIt, by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 36 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| brenipatide | Eli Lilly | phase 3 | 19 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
The one study Innovent Biologics leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05606913Diabetes Mellitus, Type 2 · China | 3 | Completed | Jan 26, 2024 | 731 |
How it is read
Names in the registry
- “Dulaglutide”, 25 entries
- “LY2189265”, 18 entries
- “dulaglutide”, 2 entries
- “Dulaglutide (Reference)”, 1 entry
- “Dulaglutide (Test)”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 44 studies
- Cardiovascular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.